Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of gastrointestinal adverse effects of opioids
2013-001540-60Phase 2Completed
- Sponsor
- Mech-Sense
- Start
- Aug 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of oxycodone and polyethylene glycol in opioid-induced bowel dysfunction (OIBD) and opioid-induced constipation (OIC) (5 arms), sponsored by Mech-Sense. Primary endpoint: Gastrointestinal transit times. Started Aug 2013; status: completed.
02
Drugs
oxycodonepolyethylene glycol
03
Conditions
opioid-induced bowel dysfunction (OIBD)opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2013-001540-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001540-60.